A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Inclusion criteria

• Locally advanced or metastatic and/or unresectable HCC
• Child-Pugh A
• Barcelona Clinic Liver Cancer stage B or C
• Eastern Cooperative Oncology Group (ECOG) Perfromance Status of 0-1
• Received an immune checkpoint inhibitor in 1L HCC treatment regimen
• Adequate hematologic and end-organ function

Exclusion criteria

• Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases as outlined in the protocol.
• History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%).
• History of autoimmune, immune deficiency, or inflammatory disorders including, but not limited to, inflammatory bowel disease, systemic lupus erythematosus, sarcoidosis, Wegener syndrome, rheumatoid arthritis, antiphospholipid antibody syndrome, Guillain-Barre syndrome, or multiple sclerosis
• History of clinically significant conditions such as but not limited to the following: renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that in Investigator's opinion, would adversely affect the subject's participation in the study.